These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36637978)

  • 1. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer.
    Tan P; Huang W; He X; Lv F; Cui Y; Du S
    J Immunother; 2023 Feb-Mar 01; 46(2):64-73. PubMed ID: 36637978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
    Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
    J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.
    Lin X; Deng H; Yang Y; Wu J; Qiu G; Li S; Xie X; Liu M; Xie Z; Qin Y; Song Y; Zhou C
    Front Oncol; 2021; 11():698832. PubMed ID: 34327140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
    Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
    Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
    Tao H; Li F; Wu D; Ji S; Liu Q; Wang L; Liu B; Facchinetti F; Leong TL; Passiglia F; Hu Y
    Transl Lung Cancer Res; 2022 Mar; 11(3):381-392. PubMed ID: 35399572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.
    Guo C; Zhang Q; Zhou P; Cheng Y; Nie L; Wang G
    Sci Rep; 2024 Jul; 14(1):17137. PubMed ID: 39060280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
    Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
    [No Abstract]   [Full Text] [Related]  

  • 15. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
    Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
    Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
    Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
    Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients.
    Li J; Chen S; Yan T; Zeng M
    J Coll Physicians Surg Pak; 2024 Mar; 34(3):302-307. PubMed ID: 38462865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
    Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
    Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.